Core Viewpoint - BioAge Labs, Inc. has announced the pricing of its upsized underwritten public offering of 5,897,435 shares at $19.50 per share, aiming to raise approximately $115.0 million before expenses [1]. Group 1: Offering Details - The offering is expected to close on or about January 23, 2026, subject to customary closing conditions [1]. - BioAge has granted underwriters a 30-day option to purchase an additional 884,615 shares [1]. - Goldman Sachs & Co. LLC, Piper Sandler, and Citigroup are acting as joint book-running managers for the offering [2]. Group 2: Use of Proceeds - The net proceeds will be used to fund research, clinical and process development, and manufacturing of product candidates, including BGE-102, as well as working capital, capital expenditures, and reduction of indebtedness [3]. Group 3: Company Overview - BioAge is a clinical-stage biopharmaceutical company focused on developing therapeutic candidates for metabolic diseases by targeting human aging biology [6]. - The lead product candidate, BGE-102, is a small-molecule NLRP3 inhibitor for cardiovascular risk and retinal diseases, with a Phase 1 trial currently underway [6].

U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Wednesday.Shares of Netflix Inc (NASDAQ:NFLX) fell sharply in pre-market trading after the company reported fourth-quarter financial results and issued first-quarter guidance below estimates.Netflix reported better-than-expected fourth-quarter financial results Tuesday after market close. Netflix said it sees first-quarter revenue of $12.16 billion versus a Street consensus estimate of $12.19 billion, according to data f ...

EMERYVILLE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced a proposed underwritten public offering in which it intends to offer and sell, subject to market and other conditions, up to $75.0 million of shares of its common stock. In addition, BioAge intends to grant the underwriters a 30-day ...

BGE-102 has the potential for therapeutic retinal exposure with oral delivery, reducing treatment burden in ocular indications currently treated with intravitreal therapies Growing preclinical and clinical evidence points to central role of the inflammasome in multiple retinal diseases where inflammation is a key feature, including diabetic macular edema (DME) BGE-102 has demonstrated favorable tolerability to date in ongoing Phase 1 trial, with robust reductions in key inflammatory biomarkers including hsC ...

BGE-102 (NLRP3 Inhibitor) - BGE-102 is a potential best-in-class NLRP3 inhibitor with an IC90 of 18 nM by human ex-vivo whole blood stimulation[23] - In obese participants, BGE-102 achieved an 86% reduction in hsCRP and normalized hsCRP (<2 mg/L) in 93% of patients after 14 days of dosing at 120 mg QD[8, 35] - Phase 1 clinical trial full data is anticipated in H1 2026[7, 32] - BGE-102 demonstrated ≥90% suppression of IL-1β for 24 hours after 14 days of dosing at 60 mg QD in healthy volunteers[35] - BGE-102 resulted in a 44-62% reduction in IL-6 in obese participants[66] APJ Agonist - Preclinical models suggest APJ agonism has the potential to double weight loss and fully restore body composition when combined with an incretin[8] - IND submission for APJ agonist is anticipated by 2026 YE[8] Financial Status - The company reported a strong balance sheet with $2959 million in cash, cash equivalents, and marketable securities as of September 30, 2025[164] Therapeutic Areas - Normalizing hsCRP (<2 mg/L) can drive a 25% reduction in MACE[83, 84]

Core Insights - BioAge Labs, Inc. announced positive interim data from the Phase 1 clinical trial of BGE-102, a novel NLRP3 inhibitor aimed at treating cardiovascular risk factors, showing significant reductions in inflammatory markers [1][4][9] Group 1: Clinical Trial Results - In a multiple ascending dose (MAD) cohort, BGE-102 at 120 mg once daily achieved an 86% median reduction in high-sensitivity C-reactive protein (hsCRP) at Day 14, with 93% of participants reaching hsCRP levels below 2 mg/L [2][7] - BGE-102 also demonstrated a 44% median reduction in serum IL-6 at Day 14, indicating its effectiveness in reducing systemic inflammation [6][12] - The drug achieved an 83% median reduction in hsCRP from a baseline of 4.85 mg/L at Day 7 and maintained an 86% reduction at Day 14 [7][9] Group 2: Safety and Tolerability - BGE-102 was well tolerated, with adverse events being infrequent, mild to moderate in severity, and self-limited, showing no dose-dependent pattern [12][14] - No dose-limiting toxicities were observed during the trial [12] Group 3: Future Development Plans - Full Phase 1 data, including additional MAD cohorts, is anticipated in the first half of 2026, with a Phase 2a study set to initiate in the same timeframe [1][13] - The Phase 2a study will evaluate BGE-102's effects on inflammatory biomarkers over a longer duration in patients with elevated cardiovascular risk [9][13] Group 4: Mechanism and Innovation - BGE-102 represents a structurally novel class of NLRP3 inhibitors with a unique mechanism and binding site, targeting age-related inflammation implicated in various diseases [14][15] - The drug's high brain penetration was confirmed, with cerebrospinal fluid concentrations exceeding the IC90 at doses of 60 mg and above [3][12]

Core Viewpoint - Premarket trading is showing significant activity with notable price movements indicating potential investment opportunities before the market opens [1] Premarket Gainers - Ventyx Biosciences, Inc. (VTYX) increased by 57% to $15.79 [3] - Cardio Diagnostics Holdings, Inc. (CDIO) rose by 36% to $4.02 [3] - Monte Rosa Therapeutics, Inc. (GLUE) saw a 28% increase to $20.54 [3] - Momentus Inc. (MNTS) gained 27% reaching $12.50 [3] - BioAge Labs, Inc. (BIOA) went up by 13% to $17.50 [3] - Neumora Therapeutics, Inc. (NMRA) increased by 11% to $2.03 [3] - Mobileye Global Inc. (MBLY) rose by 10% to $13.45 [3] - Society Pass Incorporated (SOPA) increased by 10% to $3.47 [3] - SU Group Holdings Limited (SUGP) saw an 8% rise to $6.32 [3] - Critical Metals Corp. (CRML) gained 7% reaching $12.73 [3] Premarket Losers - Evolution Metals & Technologies Corp. (EMAT) decreased by 28% to $15.20 [4] - Ascent Solar Technologies, Inc. (ASTI) fell by 12% to $4.65 [4] - Apogee Enterprises, Inc. (APOG) saw a 10% decline to $33.30 [4] - Next Technology Holding Inc. (NXTT) dropped by 8% to $8.49 [4] - AST SpaceMobile, Inc. (ASTS) decreased by 7% to $90.45 [4] - Nomadar Corp. (NOMA) fell by 7% to $3.66 [4] - EZGO Technologies Ltd. (EZGO) decreased by 7% to $1.99 [4] - Cohen & Company Inc. (COHN) saw a 6% decline to $28.30 [4] - PMGC Holdings Inc. (ELAB) dropped by 4% to $5.34 [4] - Anghami Inc. (ANGH) decreased by 3% to $4.49 [4]

Group 1: Market Overview - U.S. stocks experienced an upward trend, with the Dow Jones index increasing by approximately 200 points on Wednesday [1] Group 2: Dynavax Technologies Corp - Shares of Dynavax Technologies Corp rose significantly after Sanofi SA announced its acquisition for $15.50 per share in cash, totaling an equity value of around $2.2 billion [1] - The acquisition enhances Sanofi's position in the adult immunization market [1] - Dynavax shares surged by 38.6% to close at $15.44 on Wednesday [1] Group 3: Other Notable Stock Movements - Omeros Corp shares increased by 66.8% to $14.60 following FDA approval of YARTEMLEA for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy [3] - Edgewise Therapeutics Inc gained 23.8% to $26.94 after updates from the ongoing CIRRUS-HCM Phase 2 trial of EDG-7500 [3] - Agios Pharmaceuticals Inc shares surged by 17.9% to $29.00 after FDA approval of AQVESME for treating anemia in adults with thalassemia, priced at approximately $425,000 per patient per year [3] - Wheels Up Experience Inc saw a gain of 14.8% to $0.73 [3] - Travere Therapeutics Inc increased by 14.3% to $40.41 [3] - Coincheck Group NV shares rose by 12.5% to $2.88 [3] - Polestar Automotive Holding UK Plc jumped 11.8% to $16.92 after announcing a $300 million equity investment [3] - CapsoVision Inc gained 11.6% to $14.39 [3] - X4 Pharmaceuticals Inc increased by 9.5% to $4.52 [3] - Falcon's Beyond Global Inc shares rose by 9.4% to $18.35 following a $100 million mixed shelf offering [3] - BIOAGE Labs Inc jumped 8.8% to $14.37 [3] - Kodiak Sciences Inc gained 8.6% to $29.81 [3] - UiPath Inc increased by 7.9% to $17.23 after being announced as a replacement for Synovus Financial in the S&P MidCap 400 [3] - Immuneering Corp rose by 6.8% to $6.83, with an upcoming update on a clinical trial scheduled for January 7, 2026 [3] - Nike Inc shares gained 4.7% to $60.03 amid mixed investor sentiment regarding insider purchases and concerns over tariffs and demand in China [3] - Micron Technology Inc increased by 3.5% to $286.01 [3]

Core Viewpoint - BioAge Labs is a small biotech company that has seen a significant increase in its stock price due to clinical progress in weight management, but it remains unattractive for long-term investors due to high risks associated with its clinical stage and intense competition in the market [1][7]. Group 1: Company Overview - BioAge Labs' shares have increased by 122% year to date, currently priced at $12.88 with a market cap of $462 million [5][6]. - The company is developing a single candidate, BGE-102, which is still in phase 1 clinical trials, making it a high-risk investment [4][3]. Group 2: Clinical Development - BioAge Labs has only one candidate in clinical trials, which is in phase 1, indicating a lack of advanced clinical data compared to competitors [4][3]. - Positive interim results for BGE-102 have been reported, but the overall risk remains high due to the early stage of development [4]. Group 3: Market Competition - The weight management market is expected to grow rapidly, attracting many major pharmaceutical companies and smaller firms, increasing competition for BioAge Labs [6][7]. - Success for BioAge Labs will depend on the safety and efficacy of BGE-102, but uncertainty remains regarding its ability to compete effectively in the anti-obesity market [7]. Group 4: Investment Alternatives - Other biotech companies, such as Viking Therapeutics, are further along in clinical trials, having completed phase 2 and currently in phase 3 for their lead candidate, VK2735, presenting a less risky investment option [8]. - Investors may face the risk of BioAge Labs shares becoming worthless in the future, suggesting a cautious approach towards investment in this company [9].

BioAge Labs FY Conference Summary Company Overview - **Company**: BioAge Labs (NasdaqGS:BIOA) - **Event**: 37th Healthcare Conference at Piper Sandler - **Date**: December 04, 2025 Key Points Clinical Data Presentation - BioAge Labs presented initial clinical results for their brain-penetrant NLRP3 inhibitor, showing promising data from SAD (Single Ascending Dose) and MAD (Multiple Ascending Dose) cohorts [4][4] - The 60 mg once daily dose achieved IC90 target coverage in both the brain and periphery, while the 120 mg dose completely shut off IL-1 beta, indicating strong efficacy and safety [4][4] Focus on Cardiovascular and Metabolic Diseases - The primary endpoint for upcoming studies will focus on CRP (C-reactive protein) reduction in obese individuals with elevated cardiovascular risk factors, shifting from obesity as the primary endpoint [5][5][6] - The company believes that brain penetration is not necessary for achieving CRP reduction, as peripheral antibodies have shown similar efficacy [7][7] Indication Prioritization - BioAge Labs is exploring various indications for their inflammasome inhibitor, including neurodegenerative and ocular diseases, while focusing on cardiovascular and metabolic diseases for initial studies [11][11][12] - The company plans to communicate additional indications based on initial clinical data expected next year [12][12] Differentiation of NLRP3 Inhibitors - BioAge Labs has a novel binding site for NLRP3, which may provide advantages over existing inhibitors, including the ability to block both active and inactive forms of NLRP3 [15][15] - The company is one of only three programs with brain-penetrant NLRP3 inhibitors currently in the clinic, indicating a competitive edge in this space [16][16] Upcoming Studies and Data Readouts - Two MAD cohorts will be conducted with obese individuals, with initial CRP data expected in the first half of next year [17][17][18] - A three-month monotherapy study is planned, which will assess a broader set of biomarkers [41][41] Financial Position - BioAge Labs reported a cash balance of approximately $300 million, providing a runway of around three years to support ongoing studies and potential new indications [44][44] Pipeline Development - The company is investing in a second brain-penetrant compound and has additional peripheral compounds in development, indicating a robust pipeline strategy [45][45][46] - BioAge Labs aims to retain ownership of certain indications while considering partnerships for others, particularly those requiring significant resources [47][47] Conclusion - BioAge Labs is positioned to advance its NLRP3 inhibitor through various clinical trials targeting cardiovascular and metabolic diseases, with a strong focus on CRP reduction and potential for broader applications in neurodegenerative and ocular diseases. The company maintains a solid financial position to support its development pipeline and strategic goals [50][50]